This is the letter I just sent them, for better or worse.
Faye Bronner and Charles Watson
Food and Drug Administration
555 Winderley Place, Suite 200
Maitland, FL 32751
Ms. Faye Bronner and Mr. Charles Watson:
Hello, I am writing to you today to enquire about a study performed by the FDA this past June.
You, the Food and Drug Administration, published a report on May 4, 2009 that performed a preliminary study on electronic cigarettes. I have a few questions tht directly pertain to that study.
The results of the study can be found on the Food and Drug Administration's website at http://www.fda.gov/downloads/Drugs/ScienceResearch/UCM173250.pdf
The study compares the various test results found related to electronic cigarettes, which are marketed, by and large, as a safer alternative to smoking tobacco cigarettes; to the Nicotrol inhalation device, which is marketed as a nicotine cessation device. These two devices are marketed for very different purposes.
My first question.
Why were the two tested electronic cigarettes not tested with a standard tobacco cigarette as a control? This would make sense to those reading the study, as an electronic cigarette is meant to be a safer alternative to a tobacco cigarette, and not as a cessation device.
Now, in the results, tests were performed to determine the presence of tobacco specific nitrosamines. In the results of these tests, the nicotrol inhaler's findings were not included in the test results. The findings that demonstrated that these TSNA's were present did not provide quantifiable data as to the levels present. In addition to these, the results are not compared to a tobacco cigarette, which the electronic cigarette is meant to provide the safer alternative to.
To compare here, using studies performed by other laboratories, the total amount of TSNA's in electronic cigarettes are approximately 8ng/g, which after a full daily dose, does not reach carcinogenic levels of TSNA's. However, studies performed by other laboratories show that the Marlboro brand provide approximately 11190ng/g (which is almost 1400x the amount found in electronic cigarettes), which after a full daily dose, is far more than enough to provide carcenogenic levels.
These findings are of large import as they are one of the primary basis of the several statements given by the Food and Drug Administration that electronic cigarettes are 'bad'.
My second question.
Why were the details of TSNA's not provided in the FDA's report? This is important, since the findings show that the levels are not enough to cause them to exhibit carcinogenic properties.
The entire study was conducted with the control being a device that is used for a very different purpose, and in most of the results in the study the control's results were not given. This is an alarming fact to anyone who understands that the control is not being tested for comparison.
My third question.
Why was the Nicotrol inhaler's results not published in most of the results, when it was specifically stated to be the control? This is also important since even it would exhibit trace amounts of TSNA's, as even medical grade nicotine is extracted from tobacco.
Another issue I find pressing regarding the study is the presence of Diethylene glycol. In the results, it is stated to occur in a single sample, among 19 different samples. One sample, the control, did not have its results published regarding whether or not it had this substance present.
The results published did not state what level was present, or if it was present after several tests of the same sample. This is relevant, since Diethylene glycol is used in the production of tobacco cigarettes, notably in processing of tobacco and in production of filters.
My fourth question.
Why were the levels of Diethylene glycol not given, nor the number of times the sample was shown to exhibit it? This is important as it is found in the smoke produced by tobacco cigarettes, and would help determine if the amounts present are more or less dangerous than that which electronic cigarettes are meant to replace.
My fifth question.
Why were the results of the control not published regarding Diethylene glycol, when the presence of the Diethylene is one of the primary concerns of the Food and Drug Administration?
I would like to request the testing procedure be performed again, and use of a control or set of controls from the list of products that electronic cigarettes are meant to replace. This would include tobacco cigarettes distrubuted under the names Marlboro, Camel, Winston, Newport and others. It would not be conducive to findings to use a control or controls from any class of cessation devices, as electronic cigarettes, by and large, are not marketed as cessation devices.
Such a study would evaluate electronic cigarettes on more equal footing directly against the products they are designed to be an alternative to.
Of other note pertaining to the several announcements against electronic cigarettes, I would like to inquire as to why no reports by third parties have been named. In all documents by the FDA, it is stated there are 'no other studies' regarding the health effects of electronic cigarettes, when there have indeed been numerous studies performed.
Awaiting your reply,
FWishbringer